Clinical Trial Detail

NCT ID NCT03825796
Title CPX-351 and Enasidenib in Treating Patients With Relapsed Acute Myeloid Leukemia Characterized by IDH2 Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Jonsson Comprehensive Cancer Center
Indications

acute myeloid leukemia

Therapies

CPX-351 + Enasidenib

Age Groups: adult senior

Additional content available in CKB BOOST